New pre-analytical approach for the deep proteome analysis of sera from pancreatitis and pancreas cancer patients

Archives of Physiology and Biochemistry

Volumn 116, Issue 4-5, 2010, Pages 208-217

  Fakelman, Frederik ^a   Felix, Klaus ^a   Büchler, Markus W ^a   Werner, Jens ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoimmune pancreatitis; Biomarker; SELDI TOF MS; Serum proteomics

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEOME;

ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; FEMALE; FRACTIONATION; HIGH THROUGHPUT SCREENING; HUMAN; ION EXCHANGE CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; PANCREATITIS; PROTEIN MICROARRAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, ION EXCHANGE; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROTEIN ARRAY ANALYSIS; PROTEOME; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTRUM ANALYSIS;

EID: 78649236123     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2010.510891     Document Type: Article

References (24)

1. Anderson L. (2005). Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 563:23-60.
2. Anderson NL, Anderson NG. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics, 1:845-67.
3. Au JS, Cho WC, Yip TT, Yip C, Zhu H, Leung WW, Tsui PY, Kwok DL, Kwan SS, Cheng WW, et al. (2007). Deep proteome profling of sera from never-smoked lung cancer patients. Biomed Pharmacother 61:570-7.
4. Baumgart S, Lindner Y, Kuhne R, Oberemm A, Wenschuh H, Krause E. (2004). The contributions of specifc amino acid side chains to signal intensities of peptides in matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrum 18:863-8.
5. Boschetti E, Monsarrat B, Righetti PG. (2007). The "Invisible Proteome": How to capture the low-abundance proteins via combinatrial ligand libraries. Current Proteomics 4:198-208.
6. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, et al. (2006). Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 4:1010-16; quiz 934.
7. Dimagno E P. (1999). Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol 10 Suppl. 4:140-42.
8. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H. (2007). Identifcation of potential markers for the detection of pancreatic cancer through comparative serum protein expression profling. Pancreas 34:205-14.
9. Harper RG, Workman SR, Schuetzner S, Timperman AT, Sutton JN. (2004). Low-molecular-weight human serum proteome using ultrafltration, isoelectric focusing, and mass spectrometry. Electrophoresis 25:1299-306.
10. Hartmann D, Felix K, Ehmann M, Schnolzer M, Fiedler S, Bogumil R, Buchler M, Friess H. (2007). Protein expression profling reveals distinctive changes in serum proteins associated with chronic pancreatitis. Pancreas 35:334-42.
11. Hartwig S, Czibere A, Kotzka J, Passlack W, Haas R, Eckel J, Lehr S. (2009). Combinatorial hexapeptide ligand libraries (ProteoMiner): an innovative fractionation tool for diferential quantitative clinical proteomics. Arch Physiol Biochem 115:155-60.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Tun MJ. (2008). Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
13. Kiehntopf M, Siegmund R, Deufel T. (2007). Use of SELDI-TOF mass spectrometry for identifcation of new biomarkers: potential and limitations. Clin Chem Lab Med 45:1435-49.
14. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan D W, Goggins M. (2004). Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860-68.
15. Li L, Sun C, Freeby S, Yee D, Kiefer-Jaquinod S, Luc Guerrier L, Boschetti E, Lomas L. (2009). Protein sample treatment with peptide ligand library: Coverage and consistency. J Proteomics Bioinform 2:485-94.
16. Murr MM, Sarr MG, Oishi AJ, Van Heerden JA. (1994). Pancreatic cancer. CA Cancer J Clin 44:304-18.
17. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-10.
18. Righetti PG, Boschetti E, Lomas L, Citterio A. (2006). Protein equalizer technology: The quest for a "democratic proteome". Proteomics 6:3980-92.
19. Righetti PG, Castagna A, Antonioli P, Boschetti E. (2005). Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 26:297-319.
20. Rosewicz S, Wiedenmann B. (1997). Pancreatic carcinoma. Lancet 349:485-9.
21. Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Buchler MW. (2005). Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 92:547-56.
22. Tulasiraman V, Lin S, Gheorghiu L, Lathrop J, Lomas L, Hammond D, Boschetti E. (2005). Reduction of the concentration diference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26:3561-71.
23. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. (2003). Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096-103.
24. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. (2004). Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586-94.